The development of predictors of multiple sclerosis (MS) disability is difficult due to the complex interplay of pathophysiological and adaptive processes.
Objective:
The purpose of this study was to investigate whether combined evoked potential (EP)-measures allow prediction of MS disability after 20 years.
Methods:
We examined 28 patients with clinically definite MS according to Poser’s criteria with Expanded Disability Status Scale (EDSS) scores, combined visual and motor EPs at entry (T0), 6 (T1), 12 (T2) and 24 (T3) months, and a cranial magnetic resonance imaging (MRI) scan at T0 and T2. EDSS testing was repeated at year 14 (T4) and year 20 (T5). Spearman rank correlation was used. We performed a multivariable regression analysis to examine predictive relationships of the sum of z-transformed EP latencies (s-EPT0) and other baseline variables with EDSST5.
Results:
We found that s-EPT0 correlated with EDSST5 (rho=0.72, p<0.0001) and ΔEDSST5-T0 (rho=0.50, p=0.006). Backward selection resulted in the prediction model: E (EDSST5)=3.91–2.22×therapy+0.079×age+0.057×s-EPT0 (Model 1, R2=0.58) with therapy as binary variable (1=any disease-modifying therapy between T3 and T5, 0=no therapy). Neither EDSST0 nor T2-lesion or gadolinium (Gd)-enhancing lesion quantities at T0 improved prediction of EDSST5. The area under the receiver operating characteristic (ROC) curve was 0.89 for model 1.
Conclusions:
These results further support a role for combined EP-measures as predictors of long-term disability in MS.
PittockSJMcClellandRLMayrWT. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol2004; 56: 303–306.
2.
SayaoALDevonshireVTremlettH. Longitudinal follow-up of ‘benign’ multiple sclerosis at 20 years. Neurology2007; 68: 496–500.
3.
CostelloeLThompsonAWalshC. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry2008; 79: 1245–1248.
4.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
5.
RunmarkerBAnderssonCOdénA. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol1994; 241: 597–604.
6.
ConfavreuxCVukusicSMoreauT. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
7.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126: 770–782.
8.
O’RiordanJIThompsonAJKingsleyDP. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain1998; 121: 495–503.
9.
FisnikuLKBrexPAAltmannDR. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
10.
RovarisMConfavreuxCFurlanR. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol2006; 5: 343–354.
11.
KapposLMoeriDRadueEW. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet1999; 353: 964–969.
12.
IzquierdoGAnguloSGarcia-MorenoJM. Intrathecal IgG synthesis: Marker of progression in multiple sclerosis patients. Acta Neurol Scand2002; 105: 158–163.
13.
BergerTRubnerPSchautzerF. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med2003; 349: 139–145.
14.
LalivePHMengeTDelarasseC. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A2006; 103: 2280–2285.
15.
KuhleJPohlCMehlingM. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med2007; 356: 371–378.
16.
BrettschneiderJCzerwoniakASenelM. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One2010; 5: e11986.
17.
SimpsonSJrTaylorBDwyerDE. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler2012; 18: 799–806.
18.
TeunissenCESombekkeMvan WinsenL. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler2012; 18: 1092–1098.
19.
FreedmanMSMetzigCKapposL. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: A BENEFIT study analysis. Mult Scler2012; 18: 966–973.
20.
LeocaniLRovarisMBoneschiFM. Multimodal evoked potentials to assess the evolution of multiple sclerosis: A longitudinal study. J Neurol Neurosurg Psychiatry2006; 77: 1030–1035.
21.
KallmannBAFackelmannSToykaKV. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler2006; 12: 58–65.
22.
InvernizziPBertolasiLBianchiMR. Prognostic value of multimodal evoked potentials in multiple sclerosis: The EP score. J Neurol2011; 258: 1933–1939.
23.
FuhrPBorggrefe-ChappuisASchindlerC. Visual and motor evoked potentials in the course of multiple sclerosis. Brain2001; 124: 2162–2168.
24.
JungPBeyerleAZiemannU. Multimodal evoked potentials measure and predict disability progression in early relapsing–remitting multiple sclerosis. Mult Scler2008; 14: 553–556.
25.
SchlaegerRD’SouzaMSchindlerC. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol2012; 123: 406–410.
26.
SchlaegerRD’SouzaMSchindlerC. Prediction of long-term disability in multiple sclerosis. Mult Scler2012; 18: 31–38.
27.
PoserCMPatyDWScheinbergL. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol1983; 13: 227–231.
28.
KapposLLechner-ScottJWuS. Neurostatus.net: Independent internet platform for training and certification of physicians participating in projects that use a standardised, quantified neurological examination and assessment of Kurtzke’s Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis, http://www.neurostatus.net. (2007, accessed 4 July 2013).
29.
Lechner-ScottJKapposLHofmanM. Can the Expanded Disability Status Scale be assessed by telephone?Mult Scler2003; 9: 154–159.
30.
StoehrM. Somatosensible Reizantworten von Nerven, Rückenmark und Gehirn. In: StoehrMDichgansJBuettnerUWHessCW (eds) Evozierte potentiale. 3rd ed.Heidelberg: Springer Verlag, 1996, pp.72, 625–627.
31.
MargaritellaNMendozziLGaregnaniM. Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis. Neurol Sci2012; 33: 887–892.
32.
GoodinDSRederATEbersGC. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFN beta-1b trial. Neurology2012; 78: 1315–1322.
33.
VucicS. The re-emergence of evoked potentials in multiple sclerosis: From diagnosis to prognostication. Clin Neurophysiol2012; 123: 221–222.
34.
OnofrjMGambiDBazzanoS. Evoked potentials (EPs) in experimental allergic encephalomyelitis: A study of EP modifications during the course of a controlled disease. Electromyogr Clin Neurophysiol1992; 32: 125–135.
35.
Mazón PeláezIVoglerSStraussU. Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: Correlation with incidence, onset and severity of disease. Hum Mol Genet2005; 14: 1977–1989.
36.
AmadioSPluchinoSBriniE. Motor evoked potentials in a mouse model of chronic multiple sclerosis. Muscle Nerve2006; 33: 265–273.
37.
PelayoRMontalbanXMinovesT. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?Mult Scler2010; 16: 55–61.
38.
Pallix-GuyotMGuennocAMBlascoH. Predictive value of motor evoked potentials in clinically isolated syndrome. Acta Neurol Scand2011; 124: 410–416.
39.
MargaritellaNMendozziLGaregnaniM. Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: A hint for an early identification of benign MS?BMC Neurol2012; 12: 80.
